In people with lingering severe fatigue post-COVID-19 and without chronic cardiac, pulmonary, or renal dysfunction one likely explanation for the chronic fatigue is a state of chronic low-grade neuroinflammation (14)
As a secondary outcome of the AWARD-7 trial, which evaluated the effects of dulaglutide treatment in people with T2D and CKD, one year of treatment with dulaglutide resulted in a higher estimated glomerular filtration rate compared with insulin glargine (73)
These minor reactions are generally short-lived and manageable, but they highlight the importance of monitoring the application site for any changes
Patients report noticeable improvement in headache, nausea, and mental clarity within 3060 minutes
Dont work overnight
In some cases, individuals have reported darkening of the skin, particularly in moles or freckles